- HC Wainwright has assumed coverage on Scholar Rock Holding Corp (NASDAQ:SRRK) with a Buy rating and price target of $30.
- The analyst writes that with a positive readout from the Phase 2 TOPAZ study under their belt, Scholar Rock’s apitegromab (SRK-015) is shaping to be a transformative therapeutic for Type 2/3 Spinal Muscular Atrophy (SMA).
- HC Wainwright says that recent 24-Month TOPAZ extension data further convinces that apitegromab can solidify a place in the SMA market (2025 est. approval) by being a muscle-directed therapy that can complement current SMN therapies.
- Apitegromab showed a mean HFMSE change of +4.4 points, with 81% of patients achieving a ≥1 point increase and 56% achieving ≥3 points.
- Scholar Rock is currently enrolling patients for its pivotal Phase 3 SAPPHIRE study, which KOLs indicate may deliver equal, if not better results, as the design is influenced by TOPAZ.
- Price Action: SRRK shares are up 2.75% at $9.16 on the last check Monday.
CEI’s Subsidiary Provides Update on Patent for Medical Waste Treatment Technology
https://www.accesswire.com/708864/CEIs-SubsidiaryProvides-Update-on-Patent-for-Medical-Waste-Treatment-Technology
